Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection

Sehovic, Emir; Urru, Sara; Chiorino, Giovanna; Doebler, Philipp

doi:10.1186/s12885-022-09698-8

BMC Cancer

Table 2 General information about the studies included in the meta-analysis. The references of the studies were marked with an asterix symbol in the References section

From: Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection

Authors	Year	Country^a	Source	Sample size (Healthy controls + benign)^b	Index test (model)	Diagnostic Performance^c
Swellam et al. [36]	2019	Egypt	Serum	182 (39 + 47)	- miR-21	0.857
					- miR-126	0.998
					- miR-155	0.995
				111 (39 + 47)^d	- miR-21	0.400/0.930
					- miR-126	0.760/1.000
					- miR-155	0.958/0.965
Zhang et al. [37]	2017	China	Whole Blood	28 (13)	- miR-30b-5p	0.933
					- miR-96-5p	0.769
					- miR-182-5p	0.759
					- miR-374b-5p	0.826
					- miR-942-5p	0.813
Mar-Aguilar et al. [38]	2013	Mexico	Serum	71 (10)	- miR-10b	0.950
					- miR-21	0.950
					- miR-125b	0.950
					- miR-145	0.978
					- miR-155	0.994
					- miR-191	0.794
					- miR-382	0.967
					- miR-145/miR-155/miR-382	0.988
Wu et al. [39]	2012	China	Serum	100 (50)	- miR-222-3p	0.670
Diansyah et al. [40]	2021	Indonesia	Plasma	42 (16)	- miR-21	0.923
Hosseini Mojahed et al. [41]	2020	Iran	Serum	72 (36)	- miR-155	0.890
Pena-Cano et al. [42]	2019	Mexico	Serum	100 (50)	- miR-195-5p	0.882
Kim et al. [43]	2020	South Korea	Plasma	60 (30)	- miR-202	0.950
Heydari et al. [44]	2018	Iran	Serum	80 (40)	- miR-140-3p	0.660
Motamedi et al. [45]	2019	Iran	Plasma	47 (24)	- miR-21	0.828
Swellam et al. [46]	2019	Egypt	Serum	150 (30 + 40)	- miR-17-5p	0.871
					- miR-155	0.993
					- miR-222-3p	0.863
				103 (30 + 40)^d	- miR-17-5p	1.000/0.757
					- miR-155	0.935/0.944
					- miR-222-3p	1.000/0.786
Matamala et al. [47]	2015	Spain	Plasma	230 (116)	- miR-505-5p	0.721
					- miR-96-5p	0.717
					- miR-125b-5p	0.637
					- miR-21	0.607
Li et al. [48]	2019	China	Plasma	226 (113)	- let-7b-5p/miR-122-5p/miR-146-5p/miR-210-3p/miR-215-5p	0.966
Han et al. [49]	2017	China	Serum	120 (21)	- miR-21	0.788
				71 (21)	- miR-125b	0.559
				120 (21)	- miR-145	0.587
				70 (21)	- miR-155	0.749
				120 (21)	- miR-365	0.795
				70 (21)	- miR-21/miR-155	0.868
				70 (21)	- miR-21/miR-155/miR-365	0.918
				120 (21)	- miR-21/miR-365	0.868
Zhao et al. [50]	2010	USA	Plasma	30 (15)	- let-7c	0.780
				30 (15)	- miR-589	0.850
				20 (10)	- miR-425	0.830
				20 (10)	- let-7d	0.990
Pastor-Navarro et al. [51]	2020	Spain	Serum	90 (45)	- miR-21/miR-205	0.773
					- miR-21	0.771
					- miR-205	0.649
Si et al. [52]	2013	China	Serum	120 (20)	- miR-92a	0.923
Si et al. [52]	2013	China	Serum	120 (20)	- miR-21	0.933
Freres et al. [53]	2015	Belgium	Plasma	196 (88)	- miR-16/let-7d/miR-103/miR-107/miR-148a/let-7i/miR-19b/miR-22*	0.810
Freres et al. [53]	2015	Belgium	Plasma	196 (88)	- miR-16/let-7d/miR-103/miR-181a/miR-107/miR-142-3p/miR-148a/let-7f-1/miR-199a-5p/miR-590-5p/miR-32	0.800
Schrauder et al. [54]	2012	Germany	Whole Blood	48 (24)	- miR-202	0.680
Ng et al. [55]	2013	China	Plasma	120 (50)	- miR-145/miR-451a	0.931
Li et al. [56]	2018	China	Plasma	292 (146)	- miR-106a-3p/miR-106a-5p/miR-20b-5p/miR-92a-5p	0.826
Li et al. [56]	2018	China	Serum	298 (148)	- miR-106a-5p/miR-19b-3p/miR-20b-5p/miR-92a-3p	0.965
Shen et al. [57]	2014	USA	Serum	100 (50)	- miR-133a/miR-148b	0.860
Antolin et al. [58]	2015	Spain	Whole Blood	64 (20)	- miR-200c	0.850
Antolin et al. [58]	2015	Spain	Whole Blood	37 (20)	- miR-200c	0.820
Soleimanpour et al. [59]	2019	Iran	Plasma	60 (30)	- miR-21	0.990
Soleimanpour et al. [59]	2019	Iran	Plasma	60 (30)	- miR-155	0.920
Nashtahosseini et al. [60]	2021	Iran	Serum	72 (38)	- miR-660-5p	0.774
				62 (38)^d	- miR-660-5p	0.816
				72 (38)	- miR-210-3p	0.716
				62 (38)^d	- miR-210-3p	0.652
Han et al. [61]	2020	China	Serum	182 (38)	- miR-1204	0.823
Chen et al. [18]	2016	USA	Plasma	102 (49)	- miR-21	0.613
Chen et al. [18]	2016	USA	Plasma	102 (49)	- miR-152	0.687
Yu et al. [62]	2018	China	Serum	160 (47)	- miR-21-5p/miR-21-3p/miR-99a-5p	0.895
Zou et al. [63]	2021	China	Serum	246 (122)	- let-7b-5p/miR-106a-5p/miR-16-5p/miR-19a-3p/miR-19b-3p/miR-20a-5p/miR-223-3p/miR-25-3p/miR-425-5p/miR-451a/miR-92a-3p/miR-93-5p	0.956
Fang et al. [64]	2019	China	Plasma	131 (38 + 40)	- miR-324-3p/miR-382-5p/miR-21-3p/miR-324-3p/miR-30a-5p/miR-30e-5p/miR-221-3p/miR-324-3p	0.901
Fang et al. [64]	2019	China	Plasma	131 (38 + 40)	- miR-324-3p/miR-382-5p/miR-21-3p/miR-324-3p/miR-30a-5p/miR-30e-5p/miR-221-3p/miR-324-3p	0.820
An et al. [65]	2018	China	Serum	109 (24)	- miR-24	0.716
An et al. [65]	2018	China	Serum	109 (24)	- miR-103a	0.721
Hu et al. [66]	2012	China	Serum	152 (76)	- miR-16/miR-25/miR-222/miR-324-5p	0.928
Zhang et al. [67]	2015	China	Serum	151 (93)	- miR-205	0.840
Eichelser et al. [68]	2013	Germany	Serum	160 (40)	- miR-34a	0.636
					- miR-93	0.699
					- miR-373	0.879
Wang et al. [69]	2018	China	Serum	102 (44)	- miR-130b-5p/miR-151a-5p/miR-206/miR-222-3p	0.931
					- miR-130b-5p	0.728
					- miR-151a-5p	0.796
					- miR-206	0.861
					- miR-222-3p	0.886
Zhang et al. [70]	2017	China	Plasma	125 (50)	- miR-200c	0.557
Zhang et al. [70]	2017	China	Plasma	125 (50)	- miR-141	0.582
Feliciano et al. [71]	2020	Spain	Serum	80 (60)	- miR-125b/miR-29c/miR-16/miR-1260/miR-451a	1.000/0.8167
Feliciano et al. [71]	2020	Spain	Serum	188 (92)	- miR-125b/miR-29c/miR-16/miR-1260/miR-451a	0.962/0.922
Ibrahim et al. [72]	2020	Egypt	Plasma	50 (20)	- miR-10b	0.730
					- miR-21-3p	0.780
					- miR-181a	0.700
					- miR-145	0.700
Swellam et al. [73]	2021	Egypt	Serum	94 (20 + 30)	- miR-27a	0.818/0.920
Jang et al. [74]	2021	South Korea	Plasma	136 (56)	- miR-1246	0.963
					- miR-206	0.935
					- miR-24	0.965
					- miR-373	0.935
					- miR-1246/miR-206	0.988
					- miR-1246/miR-206/miR-373	0.991
					- miR-1246/miR-206/miR-24/miR-373	0.992
Guo et al. [75]	2020	China	Plasma	79 (40)	- miR-21	0.658
Guo et al. [75]	2020	China	Plasma	79 (40)	- miR-1273 g-3p	0.633
Huang et al. [76]	2018	China	Serum	235 (107)	- let-7a	0.683
					- miR-155	0.638
					- miR-574-5p	0.891
Ashirbkekov et al. [77]	2020	Kazakhstan	Plasma	68 (33)	- miR-16-5p	0.664
					- miR-210-3p	0.713
					- miR-222-3p	0.760
					- miR-29c-3p	0.739
					- miR-145-5p	0.932
					- miR-191-5p	0.904
					- miR-21	0.705
					- miR-145-5p/miR-191-5p	0.984
					- miR-145-5p/miR-21-5p	0.932
					- miR-191-5p/miR-21-5p	0.919
					- miR-145-5p/miR-191-5p/miR-21-5p	0.984
Guo et al. [78]	2018	China	Serum	60 (30)	- miR-1915-3p	0.881
Guo et al. [78]	2018	China	Serum	60 (30)	- miR-455-3p	0.778
Cuk et al. [79]	2013	Germany	Plasma	180 (60)	- miR-127-3p	0.650
					- miR-148b	0.700
					- miR-376a	0.590
					- miR-376c	0.590
					- miR-409-3p	0.620
					- miR-652	0.750
					- miR-801	0.720
					- Panel of 7 miRs above	0.810
Raheem et al. [80]	2019	Iraq	Serum	60 (30)	- miR-34a	0.669
Zhu et al. [81]	2020	China	Serum	120 (60)	- miR-1908-3p	0.838
Ahmed Mohmmed et al. [82]	2021	Egypt	Serum	80 (30)	- miR-106a	0.947
Sadeghi et al. [83]	2021	Iran	Whole Blood	130 (60)	- miR-145	0.650/0.610
Sadeghi et al. [83]	2021	Iran	Whole Blood	130 (60)	- miR-106b-5p/miR-126-3p/miR-140-3p/miR-193a-5p/miR-10b-5p	0.790/0.860
Itani et al. [84]	2021	Lebanon	Plasma	73 (32)	- miR-21	0.760
					- miR-155	0.700
					- miR-23a	0.740
					- miR-130a	0.780
					- miR-145	0.810
					- miR-425-5p	0.830
					- miR-139-5p	0.830
					- miR-451	0.730
					- miR-145/miR-425-5p	0.830
					- miR-21/miR-23a	0.800
					- miR-21/miR-130a	0.820
					- miR-21/miR-23a/miR-130a	0.820
					-miR-145/miR-139-5p/mir-130a	0.960
					- miR-145/miR-139-5p/mir-130a/miR-425-5p	0.970
Mahmoud et al. [85]	2021	Egypt	Serum	95 (25)	- miR-185-5p	0.838
Mahmoud et al. [85]	2021	Egypt	Serum	95 (25)	- miR-301a-3p	0.899
Zou et al. [86]	2022	Multiple	Serum	374 (197)	- miR-133a-3p/miR-497-5p/mir-24-3p/miR-125b-5p/miR-377-3p/miR-374c-5p/miR-324-5p/miR-19b-3p	0.918
				379 (199)	- miR-133a-3p/miR-497-5p/mir-24-3p/miR-125b-5p/miR-377-3p/miR-374c-5p/miR-324-5p/miR-19b-3p	0.915
				325 (199)^d	- miR-133a-3p/miR-497-5p/mir-24-3p/miR-125b-5p/miR-377-3p/miR-374c-5p/miR-324-5p/miR-19b-3p	0.916
				210 (199)^e	- miR-133a-3p/miR-497-5p/mir-24-3p/miR-125b-5p/miR-377-3p/miR-374c-5p/miR-324-5p/miR-19b-3p	0.953
Zou et al. [87]	2021	Singapore	Serum	369 (100 + 196)	- miR-451a/miR-195-5p/miR-126-5p/miR-423-3p/miR-192-5p/miR-17-5p	0.873
Li et al. [88]	2022	China	Serum	98 (49)	- miR-9-5p	0.852/0.937
					- miR-17-5p	0.706/0.652
					- miR-148a-3p	0.866/0.875
Shaker et al. [89]	2021	Egypt	Serum	450 (150 + 120)	- miR-29	0.916
Shaker et al. [89]	2021	Egypt	Serum	450 (150 + 120)	- miR-182	0.970
Uyisenga et al. [90]	2021	Rwanda	Plasma	45 (18)	- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-342-3p/miR-33a-5p/miR-130a-3p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-146a-5p/miR-29a-3p/miR-126-3p	0.868
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/miR-130a-3p/miR-185-5p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-146a-5p/miR-210-3p/miR-126-3p	0.865
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/miR-130a-3p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-210-3p/miR-126-3p	0.865
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-342-3p/miR-33a-5p/miR-130a-3p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-146a-5p/miR-210-3p/miR-126-3p	0.865
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/miR-130a-3p/miR-185-5p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-146a-5p/miR-29a-3p/miR-126-3p	0.863
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/miR-130a-3p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-146a-5p/miR-210-3p/miR-126-3p	0.863
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/miR-130a-3p/let-7i-5p/miR-29b-3p/miR-146a-5p/miR-210-3p/miR-126-3p	0.861
					- let-7a-5p/miR-150-5p/miR-940/miR-33a-5p/miR-130a-3p/miR-328-3p/miR-29a-3p/miR-126-3p	0.859
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/miR-130a-3p/let-7i-5p/miR-328-3p/miR-29b-3p/miR-29a-3p/miR-126-3p	0.859
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-33a-5p/let-7i-5p/miR-29b-3p/miR-146a-5p/miR-29a-3p/miR-126-3p	0.859
					- let-7a-5p/miR-150-5p/miR-940/miR-32-5p/miR-130a-3p/miR-185-5p/let-7i-5p/miR-29b-3p/miR-146a-5p/miR-126-3p	0.859
					- let-7a-5p/miR-150-5p/miR-940/miR-130a-3p/miR-328-3p/miR-29a-3p/miR-210-3p/miR-126-3p	0.857

^aCountry from which the cases and controls of the reported model were sampled
^bSample size (cases, controls and benign) of the reported model
^cFor each reported model, its ROC AUC is shown. If not available, then the sensitivity and specificity pair are reported
^dModel with cases up to TNM stage II
^eModel with TNM stage III and IV cases

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com